{
  "completed": true,
  "status": "completed_original_source_reconciliation",
  "provider_mode": "Consensus Pro signed-in browser; observed output and citation link mappings",
  "queries": [
    "https://consensus.app/search/chromatin-accessibility-and-transcription/ff6CXBaQQI6HAWL-Q4BnoQ/"
  ],
  "query_record_note": "Exact visible question/response retained privately in raw browser receipt.",
  "primary_comparison_count": 8,
  "primary_comparisons": [
    {
      "pmid": "37922899",
      "doi": "10.1016/j.cell.2023.10.006",
      "source_type": "primary study report",
      "study_group": "PMID37922899",
      "access_depth": "full_text_partial",
      "consensus_aspect": "EP400 compensation: accessibility and expression recovery",
      "result_comparison": "Provider said this original was unavailable. Actual original Results1/2/6/8/25/26 show early SWI/SNF inhibition loses accessibility and transcription; EP400 restores both at many promoters. Above-control ATAC in clusters3/4 does not yield broadly above-control transcription. Do not describe every recovered promoter as failing expression recovery or provider search absence as a field gap.",
      "original_source": "https://pubmed.ncbi.nlm.nih.gov/37922899/",
      "source_examination_receipts": [
        "deliverables\\hsef_v53_remaining_priority_16_19_2026-10-12\\chromatin-accessibility\\examinations\\original-0-12-4500.json"
      ],
      "body_receipts": [
        "deliverables\\hsef_v53_remaining_priority_16_19_2026-10-12\\chromatin-accessibility\\body-presentation-receipts\\37922899-s1-p1-2-6-8-25-26.json"
      ]
    },
    {
      "pmid": "31940339",
      "doi": "10.1371/journal.pgen.1008546",
      "source_type": "primary study report",
      "study_group": "ZEBRAFISH_NPS_PRIMING_2020",
      "access_depth": "full_text_partial",
      "consensus_aspect": "Polymerase-independent developmental priming with an exception",
      "result_comparison": "Provider did not retrieve this original. Results2/4/7/12 show most early zebrafish opening persists under alpha-amanitin and precedes gene activation. Hypertranscribed miR430 loses opening, a specific exception. No universal statement that all accessibility requires transcription or that transcription is irrelevant is justified.",
      "original_source": "https://pubmed.ncbi.nlm.nih.gov/31940339/",
      "source_examination_receipts": [
        "deliverables\\hsef_v53_remaining_priority_16_19_2026-10-12\\chromatin-accessibility\\examinations\\original-0-12-4500.json"
      ],
      "body_receipts": [
        "deliverables\\hsef_v53_remaining_priority_16_19_2026-10-12\\chromatin-accessibility\\body-presentation-receipts\\31940339-s1-p2-4-7-12.json"
      ]
    },
    {
      "pmid": "35182480",
      "doi": "10.1016/j.molcel.2022.01.024",
      "source_type": "primary study report",
      "study_group": "ZEBRAFISH_NPS_TARGETED_RESCUE_2022",
      "access_depth": "full_text_partial",
      "consensus_aspect": "Catalytic-dead HAT separates opening from activation",
      "result_comparison": "Provider describes active-HAT bypass but omits the decisive control. Original Results7/8 show catalytic-dead dCas9-HAT restores asb11 opening without acetylation or transcription; active HAT rescues target transcription with untargeted/catalytic controls. HAT bypass does not mean opening itself is sufficient or bypassed.",
      "original_source": "https://pubmed.ncbi.nlm.nih.gov/35182480/",
      "source_examination_receipts": [
        "deliverables\\hsef_v53_remaining_priority_16_19_2026-10-12\\chromatin-accessibility\\examinations\\original-0-12-4500.json"
      ],
      "body_receipts": [
        "deliverables\\hsef_v53_remaining_priority_16_19_2026-10-12\\chromatin-accessibility\\body-presentation-receipts\\35182480-s1-p1-7-8.json"
      ]
    },
    {
      "pmid": "38049663",
      "doi": "10.1038/s41588-023-01603-8",
      "source_type": "primary study report",
      "study_group": "BAF_RNAPII_COOPERATION_PUBLISHED",
      "access_depth": "full_text_partial",
      "consensus_aspect": "Transcription-stage drugs and viable time windows",
      "result_comparison": "Original Results2/3/9/14 support paused RNAPII stabilizing BAF and ATPase-dependent nucleosome eviction. Triptolide shows no morphology/viability change up to2hours but defects at4hours, so early controlled evidence cannot license all late samples. PRC2-repressed and H3K9me3 constitutive regions differ.",
      "original_source": "https://pubmed.ncbi.nlm.nih.gov/38049663/",
      "source_examination_receipts": [
        "deliverables\\hsef_v53_remaining_priority_16_19_2026-10-12\\chromatin-accessibility\\examinations\\original-0-12-4500.json"
      ],
      "body_receipts": [
        "deliverables\\hsef_v53_remaining_priority_16_19_2026-10-12\\chromatin-accessibility\\body-presentation-receipts\\38049663-s1-p2-3-9-14.json"
      ]
    },
    {
      "pmid": "38811575",
      "doi": "10.1038/s41467-024-48911-z",
      "source_type": "primary study report",
      "study_group": "PMID38811575",
      "access_depth": "full_text_partial",
      "consensus_aspect": "Acute BRG1 interpretation and changed-site denominator",
      "result_comparison": "Original Results0/2/7/14 confirm endogenous AID baseline controls, nascent versus stable-RNA differences, and cross-cell-state experiments. Provider's96%figure concerns changed DHSs, not every DHS in the genome. Drug-treatment text and figure captions differ between10and12hours; no invented unified time is used.",
      "original_source": "https://pubmed.ncbi.nlm.nih.gov/38811575/",
      "source_examination_receipts": [
        "deliverables\\hsef_v53_remaining_priority_16_19_2026-10-12\\chromatin-accessibility\\examinations\\original-0-12-4500.json"
      ],
      "body_receipts": [
        "deliverables\\hsef_v53_remaining_priority_16_19_2026-10-12\\chromatin-accessibility\\body-presentation-receipts\\38811575-s1-p0-2-7-14.json"
      ]
    },
    {
      "pmid": "33558760",
      "doi": "10.1038/s41588-021-00777-3",
      "source_type": "primary study report",
      "study_group": "PMID33558760",
      "access_depth": "full_text_partial",
      "consensus_aspect": "Fast ATAC effects versus early transcription and tag baseline",
      "result_comparison": "Provider omitted this original. Actual Results0/1/5/6 verify rapid degron/inhibitor effects and nontoxic inhibitor controls, but the dTAG clone starts with approximately50%SMARCA4 and altered baseline. Few strong early PRO-seq changes do not demonstrate immediate global transcription loss or refute later dependency.",
      "original_source": "https://pubmed.ncbi.nlm.nih.gov/33558760/",
      "source_examination_receipts": [
        "deliverables\\hsef_v53_remaining_priority_16_19_2026-10-12\\chromatin-accessibility\\examinations\\original-0-12-4500.json"
      ],
      "body_receipts": [
        "deliverables\\hsef_v53_remaining_priority_16_19_2026-10-12\\chromatin-accessibility\\body-presentation-receipts\\33558760-s0-p0-1-5-6.json"
      ]
    },
    {
      "pmid": "35858748",
      "doi": "10.1101/gr.276766.122",
      "source_type": "primary study report",
      "study_group": "PMID35858748",
      "access_depth": "abstract_metadata",
      "consensus_aspect": "Reporter activity within accessible regions",
      "result_comparison": "Original abstract verifies roughly101000accessible regions and30%containing an activator, silencer or both. Provider numbers are retained only as the reporter assay's result. The remaining70%are not proved incompetent endogenous loci, and accessible silencers need not activate their own genomic transcription.",
      "original_source": "https://pubmed.ncbi.nlm.nih.gov/35858748/",
      "source_examination_receipts": [
        "deliverables\\hsef_v53_remaining_priority_16_19_2026-10-12\\chromatin-accessibility\\examinations\\original-59-61-6000.json"
      ],
      "body_receipts": []
    },
    {
      "pmid": "37557175",
      "doi": "10.1016/j.devcel.2023.07.007",
      "source_type": "primary study report",
      "study_group": "PMID37557175",
      "access_depth": "abstract_metadata",
      "consensus_aspect": "Pioneering versus enhancer activation and publication date",
      "result_comparison": "Original2023published abstract, rather than provider2022label, reports genetically validated Zelda-dependent priming and additional patterning-factor activation. This supports separate tiers; computational fit alone does not prove state causality.",
      "original_source": "https://pubmed.ncbi.nlm.nih.gov/37557175/",
      "source_examination_receipts": [
        "deliverables\\hsef_v53_remaining_priority_16_19_2026-10-12\\chromatin-accessibility\\examinations\\original-59-61-6000.json"
      ],
      "body_receipts": []
    }
  ],
  "grade_changed": false,
  "grade_change_note": "Source-based adjudication; no independent blinded regrade claimed.",
  "raw_receipts": [
    {
      "path": "deliverables\\hsef_v53_remaining_priority_16_19_2026-10-12\\chromatin-accessibility\\consensus-browser-2026-10-12.json",
      "sha256": "6f8ec3b86ee1301a941208dda779c788b5f9ff011efca717393f63d6fbc99467"
    }
  ],
  "independent_blinded_audit": false,
  "cutoff": "2026-10-09",
  "completed_utc": "2026-10-12T20:10:21.496719+00:00",
  "conclusion": "Endpoint hierarchy, experimental scope and original-source limits determine the evidence cards; provider wording does not override them."
}